PDF(10095 KB)
Application of Porphyrin-Based Covalent Organic Frameworks in Tumor Therapy
Jiaxin Mao, Lu Zhao, Yunfeng Bai, Feng Feng
Prog Chem ›› 2025, Vol. 37 ›› Issue (7) : 978-988.
PDF(10095 KB)
PDF(10095 KB)
Application of Porphyrin-Based Covalent Organic Frameworks in Tumor Therapy
Covalent organic frameworks (COFs), as a new class of functional organic materials, have attracted extensive attention since they were first proposed in 2005. In recent years, the application in biology is particularly prominent. Porphyrin-based COFs exhibit excellent advantages, such as high crystallinity, high porosity, flexible design, easy to surface modification and so on. These remarkable features enable them to serve as carriers of various therapeutic agents for drug delivery. Due to their special structure, such as the extended conjugate structure and the strong π-π packing interaction, porphyrin-based COFs exhibit a strong absorption effect in the visible region, have excellent thermal stability and chemical stability. In addition, they can be used as photosensitizers, so they have wide application potential in tumor therapy. This article focuses on the research progress of monotherapy and combination therapy based on porphyrin-based COFs for tumor. Finally, the challenges and prospects of their preparation and application in tumor therapy are discussed.
1 Introduction
2 Por-COFs in monotherapy
2.1 Photothermal therapy (PTT) of tumor
2.2 Photodynamic therapy (PDT) of tumor
2.3 Sonodynamic therapy (SDT) of tumor
3 Por-COFs in combined therapy
3.1 Por-COFs in dual-mode therapy
3.2 Por-COFs in trimodality therapy
4 Conclusion and outlook
porphyrin-based covalent organic frameworks / tumor therapy / monotherapy / combined therapy
| [1] |
|
| [2] |
|
| [3] |
|
| [4] |
|
| [5] |
|
| [6] |
|
| [7] |
|
| [8] |
|
| [9] |
|
| [10] |
|
| [11] |
|
| [12] |
|
| [13] |
|
| [14] |
|
| [15] |
|
| [16] |
|
| [17] |
|
| [18] |
|
| [19] |
|
| [20] |
|
| [21] |
|
| [22] |
|
| [23] |
|
| [24] |
|
| [25] |
|
| [26] |
|
| [27] |
|
| [28] |
|
| [29] |
|
| [30] |
|
| [31] |
|
| [32] |
|
| [33] |
|
| [34] |
|
| [35] |
|
| [36] |
|
| [37] |
|
| [38] |
|
| [39] |
|
| [40] |
|
| [41] |
|
| [42] |
|
| [43] |
|
| [44] |
|
| [45] |
|
| [46] |
|
| [47] |
|
| [48] |
|
| [49] |
|
| [50] |
|
| [51] |
|
| [52] |
|
| [53] |
|
| [54] |
|
| [55] |
|
| [56] |
|
| [57] |
|
| [58] |
|
| [59] |
|
| [60] |
|
| [61] |
|
| [62] |
|
| [63] |
|
| [64] |
|
| [65] |
|
| [66] |
|
| [67] |
|
| [68] |
|
| [69] |
|
| [70] |
|
/
| 〈 |
|
〉 |